Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. 2011.Cassidy A, Mossman S, Olivieri A, De Ridder M, Leroux-Roels G. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines 2011; 10: 1709-1715 [PMID: 22085174 DOI:...
In high-risk individuals who have had titers checked after primary HB immunization, a small percentage of apparently healthy recipients do not mount a detectable response to the vaccine. This failure to respond is related to factors such as age (>40 years), male gender, smoking, obesity, HIV...
Hepatitis B vaccine(Cj): 一种免疫刺激剂药物,由CJ CheilJedang Corp. (CJ CheilJedang Corp.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: 免疫刺激剂,治疗领域: 感染,消化系统疾病,在研适应症: 乙型肝炎,在研机构: CJ CheilJedang Corp.。
Figure 1 shows the percentage of vaccine responders stratified by CD4 T cell count prior to vaccination. Table 3. Multivariable analysis of factors associated with response to hepatitis B vaccination Risk factorRelative risk [95% CI]P-value Female gender 1.34 [0.78–2.32] 0.213 Receipt of ART ...
hepatitis B vaccination of infants to interrupt transmission. In 1994, the ACIP expanded the recommendations to include previously unvaccinated children aged 11-12 years.2The percentage of children aged 19-35 months who have received three doses of hepatitis B vaccine has increased substantially from...
Background: Hepatitis A and B are two of the mostdoi:10.1586/14760584.2016.1150182Marina BakkerEveline M. BungeCinzia MaranoMarc de RidderLaurence De MoerloozeImmunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review [ J]. Expert Rev Vac- cine...
In 2016 the World Health Organization set the goal of eliminating hepatitis B globally by 2030. Horizontal transmission has been greatly reduced in most countries by scaling up coverage of the infant HBV vaccine series, and vertical transmission is there
hepatitis B-related liver cancer, hepatitis B vaccine immunization program, cost analysis, incremental cost-effectiveness ratio, marginal effectiveness References [1] Shimakawa Y, Seck A, Nayagam S, et al. Screening strategies to prevent mother-to-child transmission of hepatitis B in sub-Sahara...
Stephenne J: Recombinant versus plasma-derived hepatitis-B vaccines: issues of safety, immunogenicity and cost-effectiveness. Vaccine 1988, 6: 299–303. Google Scholar Zajac BA, West DJ, McAleer WJ, Scolnick EM: Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. Jo...
Current consensus does not support the use of a universal booster of hepatitis B virus (HBV) vaccine because there is an anamnestic response in almost all children 15 years after universal infant HBV vaccination. We aimed to provide a booster strate